Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;34(6):1505-11.
doi: 10.3892/ijo_00000279.

Role of RLIP76 in doxorubicin resistance in lung cancer

Rit Vatsyayan  1 , Pankaj Chaudhary, Poorna Chandra Rao Lelsani, Preeti Singhal, Yogesh C Awasthi, Sanjay Awasthi, Sharad S Singhal
Affiliations
Review

Role of RLIP76 in doxorubicin resistance in lung cancer

Rit Vatsyayan et al. Int J Oncol. 2009 Jun.

Abstract

Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of doxorubicin (panel A). Schematic representation of RLIP76 domains (panel B).
See this image and copyright information in PMC

References

    1. Arriagada R, Le Péchoux C, Pignon JP. Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer. 2003;42:S57–S64. - PubMed
    1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355:479–485. - PubMed
    1. Dalpiaz O, al Rabi N, Galfano A, Martignoni G, Ficarra V, Artibani W. Small cell carcinoma of the bladder: a case report and a literature review. Arch Esp Urol. 2003;56:197–202. - PubMed
    1. Filipits M, Pohl G, Stranzl T, et al. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res. 2003;9:820–826. - PubMed
    1. Volm M, Koomagi R, Rittgen W. Cellular predictive factors of drug resistance in non-small cell lung carcinomas. Methods Mol Med. 2003;75:39–51. - PubMed

Publication types

MeSH terms